The RPM Report held a roundtable discussion with Office of New Drugs Director John Jenkins, Office of Surveillance and Epidemiology Director Gerald Dal Pan and Office of Medical Policy Director Bob Temple, who discussed drug safety, FDA approvals, comparative effectiveness and the future of drug development. In discussing the number of approvals for new molecular entities, Jenkins said, "We can't have an approval goal because that puts the wrong focus on our activities -- we have to be independent reviewers and observers of the data, not cheerleaders for a particular product," adding, "That's not to say we don't get excited about certain drugs that look like they're really therapeutic advances, priority drugs that really look like they're advancing the care of the patients who need them."

Related Summaries